# DESCRIPTION

## FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

- disclose government rights

## BACKGROUND

- motivate nSMase2 inhibitors

## SUMMARY

- introduce DPTIP for treating nSMase2 diseases
- specify diseases with elevated ceramide
- list specific neurodegenerative diseases
- list specific cardiac diseases
- outline various methods using DPTIP

## DETAILED DESCRIPTION

- provide context for embodiments
- disclaim limitations of embodiments

### I. Discovery of 2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a Small Molecule Inhibitor of Neutral Sphingomyelinase 2 (nSMase-2) for the Treatment of Neurodegenerative and Oncologic Diseases

- introduce DPTIP as nSMase2 inhibitor
- describe unbiased screening of NCATS chemical library
- identify DPTIP as potent inhibitor of nSMase2
- describe properties of DPTIP
- compare DPTIP to GW4869
- motivate need for nSMase2 inhibitor
- describe therapeutic utilities of nSMase2 inhibition
- list neurodegenerative diseases associated with nSMase2
- describe method for treating neurodegenerative disease
- define neurodegenerative disease
- list examples of neurodegenerative diseases
- describe method for treating cancer
- define cancer
- list examples of cancers
- describe method for treating cardiac disease
- define cardiac disease
- list examples of cardiac diseases
- describe method for inhibiting nSMase2
- describe method for inhibiting exosome biosynthesis
- describe method for inhibiting ceramide biosynthesis
- describe use of DPTIP for producing medicament
- define inhibit
- define treating
- describe subject
- describe effective amount
- describe combination therapy
- describe administration of DPTIP and additional therapeutic agent
- describe simultaneous administration
- describe sequential administration
- describe single pharmaceutical composition
- describe separate pharmaceutical compositions
- describe timing of administration
- describe administration within minutes
- describe administration within days
- describe administration of DPTIP and additional therapeutic agent
- describe single dosage form
- describe separate dosage forms
- describe adjuvants
- describe adjunct therapy
- describe combination therapy
- introduce DPTIP as small molecule inhibitor of nSMase-2
- describe administration of DPTIP in combination with other agents
- define synergy and synergistic effect
- explain Synergy Index (SI) calculation
- describe pharmaceutical compositions and administration
- introduce pharmaceutically acceptable excipients
- describe base addition salts
- describe acid addition salts
- provide examples of pharmaceutically acceptable salts
- describe formulation for therapeutic and/or diagnostic applications
- introduce modes of administration
- describe timed- or sustained-slow release forms
- provide examples of routes of administration
- describe formulation for injection
- describe transmucosal administration
- introduce pharmaceutically acceptable inert carriers
- describe oral administration formulations
- describe nasal or inhalation delivery formulations
- determine effective amounts of active ingredients
- provide examples of dosages
- describe pharmaceutical compositions for oral use
- introduce excipients and auxiliaries
- describe dragee cores and coatings
- describe push-fit capsules and soft, sealed capsules
- introduce stabilizers
- clarify meaning of "a," "an," and "the"
- clarify meaning of "comprise," "comprises," and "comprising"
- clarify meaning of "include" and its grammatical variants
- clarify meaning of numerical values and ranges

## EXAMPLES

- provide guidance for practicing embodiments

### Example 1

- introduce high throughput screening
- identify potent nSMase2 inhibitor
- describe DPTIP's potency and pharmacokinetic profile
- motivate nSMase2 inhibition for AD treatment
- summarize ceramide's role in AD
- describe nSMase2's role in AD
- discuss limitations of current nSMase2 inhibitors
- introduce high throughput screening campaign
- describe assay development for nSMase2 activity
- optimize assay parameters
- validate assay for HTS
- screen compound libraries
- analyze hits and eliminate false positives
- identify DPTIP as a potent nSMase2 inhibitor
- determine DPTIP's IC50
- evaluate DPTIP's mode of inhibition
- show DPTIP's selectivity for nSMase2
- evaluate DPTIP's metabolic stability
- determine DPTIP's pharmacokinetic profile
- show DPTIP's brain penetration
- evaluate DPTIP's ability to inhibit exosome release
- compare DPTIP to its inactive analog
- describe astrocyte activation and exosome release
- evaluate DPTIP's ability to inhibit biomarkers of brain inflammation
- compare DPTIP to its inactive analog in vivo
- describe IL-1Î²-induced EV release and cytokine regulation
- evaluate DPTIP's effect on EV release and cytokine regulation
- show DPTIP's effect on neutrophil migration
- compare DPTIP to its inactive analog in neutrophil migration
- discuss the role of astrocytes in EV release and brain inflammation
- discuss the potential of nSMase2 inhibition for AD treatment
- summarize the results of the HTS campaign
- describe the development of the 1536-well cell-free human recombinant nSMase2 enzyme activity assay
- optimize the assay protocol
- validate the assay for HTS
- screen the Molecular Libraries Small Molecule Repository
- screen the NCGC pharmaceutical collection library
- analyze hits and eliminate false positives
- confirm hits in a 7-dose-response human nSMase2 confirmatory assay
- evaluate the potency and response of confirmed hits
- select DPTIP as the most promising compound
- summarize the results of the study
- summarize DPTIP
- describe methods
- express human nSMase2
- describe fluorescence-based nSMase2 activity assay
- determine IC50 of selected compounds
- synthesize and characterize DPT
- determine metabolic stability
- determine in vivo pharmacokinetics
- inhibit exosome release from primary glial cells
- inhibit exosome release in vivo
- quantify plasma EVs
- perform western analysis
- measure cytokine levels
- perform immunohistochemistry
- describe expression of human nSMase2
- describe fluorescence-based nSMase2 activity assay
- describe HTS campaign
- describe counter-assay
- determine IC50 of selected compounds
- describe synthesis of DPT
- characterize DPT
- determine metabolic stability
- describe in vivo pharmacokinetics
- inhibit exosome release from primary glial cells
- inhibit exosome release in vivo
- quantify plasma EVs
- perform western analysis
- measure cytokine levels
- perform immunohistochemistry
- describe striatal injections
- describe EV measurements
- describe RNA isolation
- describe quantitative real-time PCR

